Iovance Biotherapeutics Inc. (NASDAQ: IOVA) is -1.88% lower on its value in year-to-date trading and has touched a low of $5.42 and a high of $18.73 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The IOVA stock was last observed hovering at around $6.16 in the last trading session, with the day’s gains setting it 0.11%.
Currently trading at $6.27, the stock is 1.42% and -6.33% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 4.46 million and changing 1.79% at the moment leaves the stock -40.30% off its SMA200. IOVA registered -55.81% loss for a year compared to 6-month loss of -49.92%.
The stock witnessed a 3.47% gain in the last 1 month and extending the period to 3 months gives it a -28.83%, and is -3.24% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 5.29% over the week and 6.14% over the month.
Distance from 52-week low is 15.68% and -66.52% from its 52-week high.
The EPS is expected to shrink by -18.90% this year.
Iovance Biotherapeutics Inc. (IOVA) Top Institutional Holders
The shares outstanding are 157.82M, and float is at 146.85M with Short Float at 14.78%.
Iovance Biotherapeutics Inc. (IOVA) Insider Activity
The most recent transaction is an insider purchase by MCPEAK MERRILL A,the company’sDirector. SEC filings show that MCPEAK MERRILL A bought 10,000 shares of the company’s common stock on Dec 21 at a price of $6.15 per share for a total of $61500.0. Following the purchase, the insider now owns 70150.0 shares.
Iovance Biotherapeutics Inc. disclosed in a document filed with the SEC on Dec 02 that Rothbaum Wayne P. (Director) bought a total of 10,000,000 shares of the company’s common stock. The trade occurred on Dec 02 and was made at $6.50 per share for $65.0 million. Following the transaction, the insider now directly holds 18.07 million shares of the IOVA stock.
Still, SEC filings show that on Nov 29, MCPEAK MERRILL A (Director) acquired 10,000 shares at an average price of $6.31 for $63100.0. The insider now directly holds 238,633 shares of Iovance Biotherapeutics Inc. (IOVA).
Iovance Biotherapeutics Inc. (IOVA): Who are the competitors?
The company’s main competitors (and peers) include Pfizer Inc. (PFE) that is trading -15.75% down over the past 12 months and Merck & Co. Inc. (MRK) that is 35.24% higher over the same period.